ClinVar Miner

Submissions for variant NM_000702.4(ATP1A2):c.1882G>A (p.Val628Met) (rs1553245659)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000521836 SCV000617441 pathogenic not provided 2017-03-13 criteria provided, single submitter clinical testing The V628M pathogenic variant in the ATP1A2 gene has been reported previously in association with familial hemiplegic migraine (FHM) (Vanmolkot et al., 2006; Mjaset et al., 2008). Functional studies demonstrate V628M expressing cells result in lower survival rate than wild type cells, affect the phosphorylation reaction, and compromise pump function under physiological conditions (Vanmolkot et al., 2006; Schack et al., 2012). The V628M variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The V628M variant is a conservative amino acid substitution, which occurs at a position that is conserved across species. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. We interpret V628M as a pathogenic variant

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.